BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 5,020.00
+25.00 (0.50%)
At close: Apr 3, 2026
BioNote Revenue
In the year 2025, BioNote had annual revenue of 118.32B KRW with 15.12% growth. BioNote had revenue of 27.97B in the quarter ending December 31, 2025, with 13.05% growth.
Revenue
118.32B
Revenue Growth
+15.12%
P/S Ratio
4.30
Revenue / Employee
397.06M
Employees
298
Market Cap
508.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.32B | 15.54B | 15.12% |
| Dec 31, 2024 | 102.78B | 12.70B | 14.10% |
| Dec 31, 2023 | 90.08B | -389.58B | -81.22% |
| Dec 31, 2022 | 479.66B | -142.70B | -22.93% |
| Dec 31, 2021 | 622.36B | -9.15B | -1.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Value Added Technology | 426.42B |
| CLASSYS | 336.82B |
| Vieworks | 230.52B |
| T&L Co., Ltd. | 164.16B |
| Dongbang Medical | 113.54B |
| Shinhung | 98.94B |
| PCL, Inc. | 4.98B |
| EOFLOW | 3.98B |